A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-11-26
Adverse events
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-21 (study day 38); relationship: Y
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-03 (study day 201); relationship: not assessed
Grade 2 Nausea — outcome: UNKNOWN; onset 2023-08-09 (study day 238); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-05 (study day 265); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-12 (study day 302); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-10-27 (study day 317); relationship: N
Data queries
No data queries.